home / stock / cspcy / cspcy quote
Last: | $3.3298 |
---|---|
Change Percent: | -0.27% |
Open: | $3.33 |
Close: | $3.3298 |
High: | $3.33 |
Low: | $3.3102 |
Volume: | 3,433 |
Last Trade Date Time: | 04/29/2024 03:00:00 am |
Quotes are delayed by 15 to 20 minutes.
Last | Open | Close | High | Low | Volume | Date |
---|---|---|---|---|---|---|
$3.3298 | $3.33 | $3.3298 | $3.33 | $3.3102 | 3,433 | 04-29-2024 |
$3.321 | $3.324 | $3.321 | $3.324 | $3.3003 | 8,981 | 04-26-2024 |
$3.25 | $3.255 | $3.25 | $3.27 | $3.2405 | 5,069 | 04-25-2024 |
$3.09 | $3.115 | $3.09 | $3.125 | $3.08 | 8,160 | 04-24-2024 |
$3.01 | $2.97 | $3.01 | $3.03 | $2.97 | 13,339 | 04-23-2024 |
$3 | $2.98 | $3 | $3.024 | $2.98 | 9,000 | 04-22-2024 |
$2.89 | $2.93 | $2.89 | $2.93 | $2.89 | 47,644 | 04-19-2024 |
$2.92 | $2.93 | $2.92 | $2.95 | $2.92 | 34,543 | 04-18-2024 |
$2.8903 | $2.898 | $2.8903 | $2.9197 | $2.89 | 36,450 | 04-17-2024 |
$2.9 | $2.9196 | $2.9 | $2.93 | $2.89 | 507,865 | 04-16-2024 |
$2.93 | $2.925 | $2.93 | $2.93 | $2.89 | 46,463 | 04-15-2024 |
$2.94 | $2.97 | $2.94 | $2.97 | $2.91 | 17,823 | 04-12-2024 |
$3.04 | $3.045 | $3.04 | $3.05 | $3.03 | 7,776 | 04-11-2024 |
$3.05 | $3.084 | $3.05 | $3.084 | $3.05 | 12,872 | 04-10-2024 |
$3.1275 | $3.11 | $3.1275 | $3.134 | $3.11 | 8,390 | 04-09-2024 |
$3.1 | $3.095 | $3.1 | $3.1196 | $3.07 | 13,234 | 04-08-2024 |
$3.0703 | $3.085 | $3.0703 | $3.11 | $3.0703 | 77,587 | 04-05-2024 |
$3.13 | $3.15 | $3.13 | $3.1597 | $3.1 | 7,212 | 04-04-2024 |
$3.1 | $3.09 | $3.1 | $3.15 | $3.09 | 42,810 | 04-03-2024 |
$3.21 | $3.19 | $3.21 | $3.21 | $3.19 | 4,487 | 04-02-2024 |
News, Short Squeeze, Breakout and More Instantly...
CSPC Pharmaceutical Group Ltd ADR Company Name:
CSPCY Stock Symbol:
OTCMKTS Market:
Elevation Oncology Highlights First-in-Human Phase 1 SYSA1801 (EO-3021) Clinical Data to be Presented by Partner CSPC Pharmaceutical Group Limited at ASCO 2023 PR Newswire Initial data showed promising signs of efficacy, including a 47.1% ORR in patients with resistant/refract...
Elevation Oncology Highlights Clinical Data for SYSA1801 (EO-3021) to be Presented by Partner CSPC Pharmaceutical Group Limited at ASCO 2023 PR Newswire NEW YORK , April 26, 2023 /PRNewswire/ -- Elevation Oncology, Inc. (Nasdaq: ELEV), an innovative oncology comp...
Corbus Pharmaceuticals expands oncology pipeline with the addition of a clinical stage Nectin-4 targeting Antibody Drug Conjugate (ADC) PR Newswire CRB-701 (SYS6002) is designed for improved therapeutic index and to act on a broad range of Nectin-4 expressing tumors ...